CLOs on the Move

ImmusanT

www.immusant.com

 
ImmusanT, Inc is a biotechnology company focused on developing a treatment, and a set of diagnostic and monitoring tools to manage patients with Celiac disease.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.immusant.com
  • One Kendall Square Suite B2004
    Cambridge, MA, MA USA 02139
  • Phone: 617.299.8399

Executives

Name Title Contact Details

Similar Companies

Polyplus Transfection

Polyplus Transfection is a San Marcos, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Sapphire Energy

Sapphire Energy believes the time is now to create new energy solutions that are environmental, scalable, and renewable. Sapphire is leading the new industrial category of Green Crude production with the potential to profoundly change America’s energy and petrochemical landscape for the better. With only sunlight and CO2, Sapphire Energy is turning algae into Green Crude that can be refined into the three most important liquid fuels we use today: gasoline, diesel and jet fuel. There is no need to make changes to our vehicles, pipelines, or distribution systems—as Green Crude offers a complete drop-in replacement solution.  

Princeton Separations Inc

Princeton Separations Inc is a Freehold, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Cradle Genomics

At Cradle Genomics, our mission is to provide knowledge that helps every pregnancy.

Finch Therapeutics

Finch Therapeutics is a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery platform to develop a novel class of orally administered biological drugs. With the capabilities to develop both complete and targeted microbiome therapeutics, Finch is advancing a rich pipeline of candidates designed to address a wide range of unmet medical needs. Finch`s lead candidate, CP101, is in late-stage clinical development for recurrent C. difficile infection (CDI). In June 2020, Finch announced that CP101 met its primary efficacy endpoint in PRISM3, the first of two pivotal trials to support the development of CP101 for the prevention of recurrent CDI. Finch is also developing CP101 for chronic hepatitis B, and FIN-211 for autism spectrum disorder. In partnership with Takeda, Finch is advancing FIN-524 and FIN-525 for ulcerative colitis and Crohn`s disease, respectively.